Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company’s products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS – SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer’s disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS – DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.